Vol 55, No 4 (2021)
Invited Editorial
Published online: 2021-06-16
Underdiagnosis and undertreatment of migraine in Poland
Abstract
Not available
References
- Olesen J. The International Classification of Headache Disorders, 3rd edition. Cephalagia. 2013; 33(9): 629–808.
- Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17(11): 954–976.
- Stępień A, Prusiński A, Suwa A, Klinika Neurologii Uniwersytetu Medycznego K, Pfizer Polska. Wybrane Dane Epidemiologiczne Występowania Migreny w Polsce (Selected Epidemiological Data on Migraine Prevalence in Poland).
- Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019; 37(4): 631–649.
- Tepper SJ. Acute Treatment of Migraine. Neurol Clin. 2019; 37(4): 727–742.
- Tfelt-Hansen P, Pascual J, Ramadan N, et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012; 32(1): 6–38.
- Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015; 55(1): 3–20.
- Kuca B, Silberstein SD, Wietecha L, et al. COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018; 91(24): e2222–e2232.
- Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019; 381(23): 2230–2241.
- Croop R, Lipton RB, Kudrow D, et al. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019; 381(2): 142–149.
- Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015; 84(7): 688–695.
- Lipton RB. Bigal ; M E, Diamond ; M, Freitag ; F, Reed ML, Stewart WF. Migraine Prevalence, Disease Burden, and the Need for Preventive Therapy. ; 2007.
- Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004; 62(5): 788–790.
- Silberstein SD, Holland S, Freitag F, et al. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012; 78(17): 1337–1345.
- Parikh SK, Silberstein SD. Preventive Treatment for Episodic Migraine. Neurol Clin. 2019; 37(4): 753–770.
- Katsarava Z, Mania M, Lampl C, et al. Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain. 2018; 19(1): 10.
- Domitrz I, Lipa A, Rożniecki JJ, et al. Migraine diagnosis and treatment in Poland: a survey among primary care practitioners. Neurol Neurochir Pol. 2021.
- Domitrz I, Lipa A, Rożniecki J, et al. Treatment and management of migraine in neurological ambulatory practice in Poland by indicating therapy with monoclonal anti-CGRP antibodies. Neurol Neurochir Pol. 2020; 54(4): 337–343.
